Comparing One Dose Versus Two Doses of Tranexamic Acid to Reduce Blood Loss in Older Adults Undergoing Surgery for Certain Hip Fractures
Led by University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje · Updated on 2026-02-27
120
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether giving one dose or two doses of tranexamic acid can safely reduce blood loss in adults aged 65 years or older undergoing surgery for certain hip fractures, specifically pertrochanteric or subtrochanteric femoral fractures. The study aims to determine if two doses lower the need for blood transfusions compared to one dose, whether tranexamic acid helps maintain higher hemoglobin levels after surgery, and if it is safe for this patient group.
Participants are randomly assigned to receive either a single intravenous dose of 15 mgkg tranexamic acid before surgery followed by a placebo, or two doses of 15 mgkg tranexamic acid, one before surgery and a second three hours later. All participants undergo standard surgical treatment within 48 hours of hospital admission, with surgery performed under spinal or general anesthesia using fixation devices appropriate for fracture type. Postoperative care includes antibiotic and thromboprophylaxis protocols, and monitoring for complications and adverse events.
During the hospital stay, researchers measure blood loss using visible and calculated methods, monitor hemoglobin and other laboratory values daily for up to three days, and record transfusions and complications. Participants are followed for safety and recovery with outpatient visits at 14 days, 1 month, 2 months, and 3 months post-surgery. The main outcome measured is the incidence of blood transfusions through postoperative day 5, with additional outcomes including hemoglobin drop, blood loss, thrombotic events, mortality, and length of hospital stay.
CONDITIONS
Brief Title
One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures
Research Team
A
Angelina Krsteva, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje
Lead Sponsor
Who Can Participate
Age: 65Years +
All Genders
Eligibility Criteria
You may qualify if you...
Written informed consent obtained
Patients aged 65 years or older
Patients with pertrochanteric femoral fracture classified as AO/OTA 31A1.2, 31A1.3, 31A2, 31A3 or subtrochanteric femoral fracture classified as AO/OTA 32
Surgical treatment performed within 48 hours of hospital admission
You will not qualify if you...
Age younger than 65 years
Known allergy or hypersensitivity to tranexamic acid
Active thromboembolic event or history of vascular event within the past year
Impaired renal function with serum creatinine >120 �b5mol/L
History of malignant disease
History of seizure disorder or chronic anticonvulsant therapy
Polytrauma or multiple trauma
More than one fracture
Previous fracture of the same hip
Preoperative hemoglobin level <8 g/dL
Thrombocytopenia or other coagulation disorders
Treatment with vitamin K antagonists with INR >1.5
Treatment with low-molecular-weight heparins without proper preoperative discontinuation
Treatment with direct oral anticoagulants without proper preoperative discontinuation
Treatment with P2Y12 inhibitors when surgery cannot be safely performed within 48 hours according to anesthesiologist assessment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment and preoperative evaluation
Surgery
Duration - Up to 2 days from hospital admission
Participants undergo surgical treatment for their hip fracture within 48 hours of admission, with anesthesia and fracture fixation according to standard care.
1 hospital admission visit including surgery
Treatment
Duration - Single dose before surgery plus a possible second dose 3 hours later
Participants receive either one or two intravenous doses of tranexamic acid to reduce blood loss during surgery.
Medication administered during hospital stay on surgery day
Surgery and Immediate Post-operative Care
Duration - Up to 3 days post-surgery
Participants are monitored closely with laboratory tests and clinical assessments daily up to 3 days after surgery to manage recovery and complications.
Daily hospital visits for 3 days postoperatively
Post-operative Follow-up
Duration - 3 months
Participants attend outpatient visits for clinical and radiographic evaluation to monitor healing and any complications up to 3 months after surgery.
Outpatient visits at 14 days, 1 month, 2 months, and 3 months post-surgery
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Improving Care for Osteoporosis After Hip Fracture in Patients 75 and Older
Comparing Nurse-Supported and Usual Treatment with Zoledronic Acid
Adaptive Platform Trial Comparing Enhanced Anesthesia Techniques and Standard Care to Reduce Neurocognitive Disorders in Elderly Patients Undergoing Hip Fracture Surgery
Review of Surgical Treatment and Outcomes in Hip Fracture Patients from 2010 to Present
Study of Liposomal Bupivacaine Plus Bupivacaine Versus Ropivacaine for Pain Control After Hip Replacement Surgery
Evaluation of Risk and Bone Changes After Hip Fracture in Chinese Older Adults Using Quantitative CT
Comparing Circum-Psoas Block and Combined Lumbar and Sacral Plexus Blocks
for Pain Relief After Hip Fracture Surgery in Older Adults
Randomized Cluster Crossover Trial Comparing Aspirin and Low Molecular Weight Heparin to Prevent Blood Clots After Hip Fracture Surgery
Early Surgery for Hip Fractures in Patients Using Direct Oral Anticoagulants
Comparing Early and Delayed Surgical Fixation Outcomes
Comparing Remimazolam and Propofol Effects on Postoperative Delirium and Recovery in Older Adults Having Hip or Knee Surgery
Study of Esketamine and Dexmedetomidine to Improve Sleep and Recovery After Hip Surgery in Older Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy and safety of tranexamic acid for patients with intertrochanteric fractures treated with intramedullary fixation: A systematic review and meta-analysis of current evidence in randomized controlled trials.
Intravenous application of tranexamic acid in intramedullary nailing for the treatment of geriatric intertrochanteric fractures: a systematic review and meta-analysis.
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.